Iron Deficiency Injectable Global Market Analysis, Trends, Growth, Research And Forecast 2033

The new report published by The Business Research Company, titled Iron Deficiency Injectable Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the iron deficiency injectable market size has grown rapidly in recent years. It will grow from $12.75 billion in 2023 to $14.06 billion in 2024 at a compound annual growth rate (CAGR) of 10.3%. The iron deficiency injectable market size is expected to see rapid growth in the next few years. It will grow to $20.68 billion in 2028 at a compound annual growth rate (CAGR) of 10.1%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=12907&type=smp

Rising Prevalence Of Pcos Fuels Demand For Iron Deficiency Injectables
The increasing prevalence of polycystic ovar*y syndrome (PCOS) is expected to propel the growth of the iron deficiency injectables market going forward. Polycystic ovar*y syndrome (PCOS) is a common hormonal disorder that affects people with ovaries, primarily women of reproductive age. Polycystic ovar*y syndrome (PCOS) leads to iron overload, which results in excessive blood loss during menstruatio*n and makes patients anemic, which can be cured by injectable iron deficiency medications. For instance, in June 2023, according to the World Health Organization, a US-based specialized health agency, globally, polycystic ovar*y syndrome (PCOS) affects an estimated 8-13% of reproductive-aged women, among whom 70% remain undiagnosed. Therefore, the prevalence Of polycystic ovar*y syndrome (PCOS) is driving the growth of the iron deficiency injectables market.

Companies Introduce Innovative Iron Deficiency Therapies Like Injectafer To Expand Market Presence
Major companies operating in the iron deficiency injectables market are developing new therapies, such as INJECTAFER, to sustain their position in the market. For instance, in June 2023, Daiichi Sankyo Company, a US-based healthcare company and American Regent Inc., a US-based injectables manufacturer, launched INJECTAFER (ferric carboxymaltose injection) for iron deficiency, which the Food And Drug Administration, a US-based government agency, approved. This is the first and only intravenous iron replacement therapy for adult patients with chronic and progressive heart failure to receive FDA approval. More than 40 clinical trials involving more than 8,800 participants from different countries were examined with INJECTAFER. This latest approval builds on INJECTAFER's successful and demonstrated use in these patients, including adult and pediatric patients with iron-deficient anemia and heart failure.

The iron deficiency injectable market covered in this report is segmented -

1) By Type: Iron Dextran; Iron Sucrose; Ferric Carboxymaltose
2) By Branded or Generics: Branded; Generics
3) By Application: Chronic Kidney Disease; Inflammatory Bowel Disease; Cancer; Other Applications
4) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=12907&type=discount

Major players in the iron deficiency injectable market are Daiichi Sankyo Company Limited, Pfizer Inc., Aetna Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A, AstraZeneca PLC, GSK PLC, Fresenius Medical Care, Teva Pharmaceutical Industries Ltd., Mylan N.V., B Braun Medical Inc., Sandoz, Fresenius Kabi AG, Cipla Limited, Emcure Pharmaceuticals Ltd., AMAG Pharmaceuticals Inc., Luitpold Pharmaceuticals Inc., Akebia Therapeutics Inc., Covis Pharma GmbH , Keryx Biopharmaceuticals Inc., Rockwell Medical Inc., American Regent Inc., Galen Medical Group.

Contents of the report:
1. Executive Summary
2. Iron Deficiency Injectable Market Report Structure
3. Iron Deficiency Injectable Market Trends And Strategies
4. Iron Deficiency Injectable Market - Macro Economic Scenario
5. Iron Deficiency Injectable Market Size And Growth
…..
27. Iron Deficiency Injectable Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/iron-deficiency-injectable-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.